StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)

Close on Nov 18, 2026Market cap $226.67MP/E –Yield –

Immuneering free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immuneering's free cash flow for the twelve months ending Sep 30, 2026 was -$61.81M. For fiscal 2025 it was -$45.49M. The highest annual figure on record is -$14.67M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.49M–
FY2024Dec 31, 2024-$55.08M–
FY2023Dec 31, 2023-$49.31M–
FY2022Dec 31, 2022-$44.84M–
FY2021Dec 31, 2021-$30.91M–
FY2020Dec 31, 2020-$14.67M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$16.80M–
Q2 FY2026Jun 30, 2026-$16.53M–
Q1 FY2026Mar 31, 2026-$18.51M–
Q4 FY2025Dec 31, 2025-$9.96M–
Q3 FY2025Sep 30, 2025-$11.98M–
Q2 FY2025Jun 30, 2025-$9.45M–
Q1 FY2025Mar 31, 2025-$14.09M–
Q4 FY2024Dec 31, 2024-$14.52M–
Q3 FY2024Sep 30, 2024-$13.48M–
Q2 FY2024Jun 30, 2024-$11.56M–
Q1 FY2024Mar 31, 2024-$15.53M–
Q4 FY2023Dec 31, 2023-$11.95M–
Q3 FY2023Sep 30, 2023-$12.08M–
Q2 FY2023Jun 30, 2023-$10.84M–
Q1 FY2023Mar 31, 2023-$14.45M–
Q4 FY2022Dec 31, 2022-$11.82M–
Q3 FY2022Sep 30, 2022-$11.02M–
Q2 FY2022Jun 30, 2022-$9.61M–
Q1 FY2022Mar 31, 2022-$12.40M–
Q4 FY2021Dec 31, 2021-$9.25M–
Q3 FY2021Sep 30, 2021-$9.05M–
Q2 FY2021Jun 30, 2021-$6.46M–
Q1 FY2021Mar 31, 2021-$6.16M–
Q4 FY2020Dec 31, 2020-$5.49M–
Q3 FY2020Sep 30, 2020-$3.49M–

More Immuneering figures

See a number that looks wrong?